Related Experiment Video
Updated: Jul 25, 2026
17:13
Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET
Published on: April 28, 2013
16.9K
Post-transplant IgA Nephropathy
1Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
Seminars in Nephrology
|March 14, 2025
Summary
Immunoglobulin A (IgA) nephropathy often recurs after kidney transplants, impacting graft survival. Research is exploring biomarkers and autoimmune mechanisms for better post-transplant IgA nephropathy management.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Immunoglobulin A (IgA) nephropathy is a leading cause of kidney failure globally.
- Kidney transplantation is the primary treatment for end-stage renal disease due to IgA nephropathy.
- Recurrence of IgA nephropathy post-transplant is common and reduces graft longevity.
Purpose of the Study:
- To review risk factors, clinical presentation, and management strategies for post-transplant IgA nephropathy.
- To highlight the need for biomarker validation in the context of kidney transplantation.
- To explore the potential of novel autoimmune-targeted therapies for recurrent IgA nephropathy.
Main Methods:
- Literature review of studies on IgA nephropathy recurrence after kidney transplantation.
- Analysis of recipient and donor factors associated with recurrence.
- Examination of the role of immunosuppression in modifying disease expression.
- Review of current and emerging treatment strategies.
Main Results:
- Recipient and donor characteristics influence IgA nephropathy recurrence risk, though findings vary across studies.
- Immunosuppression regimens can alter the clinical presentation of post-transplant IgA nephropathy.
- Biomarkers identified in native IgA nephropathy require validation in transplant settings.
- Current treatments for recurrent IgA nephropathy primarily rely on supportive care and evidence from native kidney disease.
Conclusions:
- Understanding autoimmune mechanisms in IgA nephropathy offers potential therapeutic targets for post-transplant recurrence.
- Further research is needed to validate biomarkers and refine treatment protocols for recurrent IgA nephropathy in kidney transplant recipients.
- Optimizing immunosuppression and exploring new treatments are crucial for improving allograft survival in IgA nephropathy patients.
Related Concept Videos
01:15Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:17Gastritis-II: Pathophysiology
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...